Biotech Company Marinomed Successfully Tests New Combination Drug Against Viral Respiratory Tract Infection

(firmenpresse) -



Vienna (Austria), 18 July 2018. Carrageloseombats viral infections as well as freeing up blocked airways. The study was carried out by Vienna-based biotech company Marinomed Biotech AG (Marinomed) and the results have now been published in an international journal.

Viral respiratory tract infections often cause inflammation of the nasal mucous membrane or paranasal sinuses. A comprehensive series of tests conducted by Marinomed suggest that these can be effectively treated using a combination of Carragelose

Carragelose




Original publication: Development of a nasal spray containing xylometazoline hydrochloride and iota- carrageenan for the symptomatic relief of nasal congestion caused by rhinitis and sinusitis. C. Graf, A. Bernkop-Schn


About Marinomed Biotech AG
Marinomed is a Vienna based biopharmaceutical company focusing on the development of innovative products in the field of respiratory and ophthalmological diseases based on its IP protected technology platforms.
The platform Carragelose
Marinosolv


Further information is available at www.marinomed.com and www.carragelose.com.


Contact

Dr Eva Prieschl-Grassauer
Chief Scientific Officer
Veterin
1210 Vienna, Austria
Tel. +43 (0)1 25077 4460
E-mail: eva.prieschl(at)marinomed.com
http://www.marinomed.com

Contact for media requests:

PR&D & Education
Mariannengasse 8
1090 Vienna, Austria
Tel. +43 (0)1 5057044
E-mail: contact(at)prd.at
http://www.prd.at

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Leseranfragen:
PresseKontakt / Agentur:
Bereitgestellt von Benutzer: PRD
Datum: 18.07.2018 - 04:10 Uhr
Sprache: Deutsch
News-ID 1538661
Anzahl Zeichen: 4022

contact information:
Contact person: TCJ
Town:

Wien

Phone: 01 505 70 44

Kategorie:

Pharmaceuticals & Biotech

Typ of Press Release: Unternehmensinformation
type of sending: Veröffentlichung
Date of sending: 18.07.2018
Anmerkungen:


Diese Pressemitteilung wurde bisher 516 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Biotech Company Marinomed Successfully Tests New Combination Drug Against Viral Respiratory Tract Infection
"
steht unter der journalistisch-redaktionellen Verantwortung von

PR&D (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

"BREAK EVEN": New laboratory creates excellent conditions for studying ...

Karl Landsteiner Private University in Krems opens new biomechanics laboratory Krems, 21 March 2018 − A brand new biomechanics laboratory equipped with latest technology is coming on stream at Karl Landsteiner Private University of Heal ...

Bioremediation Fungus Yields its Secrets ...

Vienna, 29. November 2017 – Thanks to genes acquired from bacteria, a fungus can degrade an environmentally harmful hydrocarbon - and comes under considerable stress in the process. These remarkable research findings, which were published recently, ...

New hope for butterfly children ...

The Greek term lysis means "dissolution" and is familiar from words such as "electrolysis". In the case of the genetic disease epidermolysis bullosa it refers to severe skin damage. Sufferers are called "butterfly children&qu ...

Alle Meldungen von PR&D